Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2004 1
2005 4
2006 4
2007 4
2008 2
2009 2
2010 2
2011 4
2012 8
2013 14
2014 15
2015 11
2016 12
2017 9
2018 9
2019 6
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Results by year
Filters applied: . Clear all
Page 1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. Among authors: tricoci p. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. Steg PG, et al. Among authors: tricoci p. Circulation. 2019 Jul 9;140(2):103-112. doi: 10.1161/CIRCULATIONAHA.118.038840. Epub 2019 May 23. Circulation. 2019. PMID: 31117810 Free PMC article. Clinical Trial.
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Szarek M, et al. Among authors: tricoci p. J Am Coll Cardiol. 2019 Feb 5;73(4):387-396. doi: 10.1016/j.jacc.2018.10.039. Epub 2018 Nov 11. J Am Coll Cardiol. 2019. PMID: 30428396 Free article. Clinical Trial.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Schwartz GG, et al. Among authors: tricoci p. Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7. Am Heart J. 2014. PMID: 25440796 Free article. Clinical Trial.
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.
Marquis-Gravel G, Dalgaard F, Jones AD, Lokhnygina Y, James SK, Harrington RA, Wallentin L, Steg PG, Lopes RD, Storey RF, Goodman SG, Mahaffey KW, Tricoci P, White HD, Armstrong PW, Ohman EM, Alexander JH, Roe MT. Marquis-Gravel G, et al. Among authors: tricoci p. J Am Coll Cardiol. 2020 Jul 14;76(2):162-171. doi: 10.1016/j.jacc.2020.05.031. J Am Coll Cardiol. 2020. PMID: 32646565
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Tricoci P, et al. N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077816 Free article. Clinical Trial.
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. White HD, et al. Among authors: tricoci p. Eur Heart J. 2019 Sep 1;40(33):2801-2809. doi: 10.1093/eurheartj/ehz299. Eur Heart J. 2019. PMID: 31121022 Free PMC article. Clinical Trial.
Promises of PAR-1 inhibition in acute coronary syndrome.
Leonardi S, Tricoci P, Mahaffey KW. Leonardi S, et al. Among authors: tricoci p. Curr Cardiol Rep. 2012 Feb;14(1):32-9. doi: 10.1007/s11886-011-0232-z. Curr Cardiol Rep. 2012. PMID: 22160877 Review.
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page